Core Points - Turn Therapeutics, a clinical-stage biotechnology company, is set to begin trading on the Nasdaq Capital Market under the ticker symbol "TTRX" on October 8, 2025 [1][2] - The company's registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission on September 30, 2025 [1] - Turn Therapeutics has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis [2] Company Overview - Turn Therapeutics focuses on developing and commercializing products for dermatology, wound care, and infectious disease [2] - The company is also pursuing global health initiatives, including thermostable vaccine delivery aimed at underserved areas worldwide [2]